JP3284240B2 - ヒトチトクロームｐ４５０ｉｉｄ６由来ペプチド断片、抗ペプチド断片抗体、及びそれらの自己免疫性肝炎の診断における応用 - Google Patents
ヒトチトクロームｐ４５０ｉｉｄ６由来ペプチド断片、抗ペプチド断片抗体、及びそれらの自己免疫性肝炎の診断における応用Info
- Publication number
- JP3284240B2 JP3284240B2 JP50076893A JP50076893A JP3284240B2 JP 3284240 B2 JP3284240 B2 JP 3284240B2 JP 50076893 A JP50076893 A JP 50076893A JP 50076893 A JP50076893 A JP 50076893A JP 3284240 B2 JP3284240 B2 JP 3284240B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- pro
- arg
- asp
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010003827 Autoimmune hepatitis Diseases 0.000 title claims abstract description 23
- 238000003745 diagnosis Methods 0.000 title claims abstract description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title claims description 35
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims description 35
- 102000007079 Peptide Fragments Human genes 0.000 title abstract description 32
- 108010033276 Peptide Fragments Proteins 0.000 title abstract description 32
- 239000012634 fragment Substances 0.000 title abstract description 21
- 230000002788 anti-peptide Effects 0.000 title abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 150000001413 amino acids Chemical class 0.000 claims abstract description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- KHTIUAKJRUIEMA-HOUAVDHOSA-N Thr-Trp-Asp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 KHTIUAKJRUIEMA-HOUAVDHOSA-N 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 abstract description 8
- 108010052832 Cytochromes Proteins 0.000 abstract description 8
- 208000006454 hepatitis Diseases 0.000 abstract description 8
- 231100000283 hepatitis Toxicity 0.000 abstract description 7
- 208000005176 Hepatitis C Diseases 0.000 abstract description 6
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 238000003748 differential diagnosis Methods 0.000 abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 33
- 230000000890 antigenic effect Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101150053185 P450 gene Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 108090000144 Human Proteins Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 102220201851 rs143406017 Human genes 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- -1 p-benzyloxybenzy l Chemical group 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 101000909129 Rattus norvegicus Cytochrome P450 2D26 Proteins 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000002529 anti-mitochondrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- NIVZHWNOUVJHKV-UHFFFAOYSA-N bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9107363A FR2677653A1 (fr) | 1991-06-17 | 1991-06-17 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
| FR91/07363 | 1991-06-17 | ||
| PCT/FR1992/000539 WO1992022656A1 (fr) | 1991-06-17 | 1992-06-16 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06510663A JPH06510663A (ja) | 1994-12-01 |
| JP3284240B2 true JP3284240B2 (ja) | 2002-05-20 |
Family
ID=9413909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50076893A Expired - Fee Related JP3284240B2 (ja) | 1991-06-17 | 1992-06-16 | ヒトチトクロームｐ４５０ｉｉｄ６由来ペプチド断片、抗ペプチド断片抗体、及びそれらの自己免疫性肝炎の診断における応用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5830667A (enExample) |
| EP (1) | EP0589993B1 (enExample) |
| JP (1) | JP3284240B2 (enExample) |
| AT (1) | ATE180512T1 (enExample) |
| CA (1) | CA2111672A1 (enExample) |
| DE (1) | DE69229269T2 (enExample) |
| ES (1) | ES2133320T3 (enExample) |
| FR (1) | FR2677653A1 (enExample) |
| WO (1) | WO1992022656A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985542A (en) * | 1996-05-20 | 1999-11-16 | Sumitomo Chemical Company, Limited | Diagnostic kit |
| DE19805815C1 (de) * | 1998-02-13 | 1999-11-11 | Ansgar W Lohse | Diagnostikum zum Erkennen der autoimmunen Hepatitis |
| DE19930933B4 (de) * | 1998-07-10 | 2005-05-25 | Imtec Immundiagnostika Gmbh | Verfahren zur Bestimmung von anti-LKM 1-Antikörpern |
| US6787303B1 (en) | 1999-04-01 | 2004-09-07 | Alton Ochsner Medical Foundation | Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis |
| CA2421680A1 (en) * | 2000-09-29 | 2002-04-04 | Merck & Co., Inc. | Antibodies for human cytochrome p450 2d6 |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| EP2454276A4 (en) * | 2008-07-17 | 2013-07-10 | Inter K Pty Ltd | THERAPEUTIC AGENTS |
| CN102955030A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体ana的试剂盒及其检测方法 |
| CN102707055A (zh) * | 2012-06-11 | 2012-10-03 | 郑州安图绿科生物工程有限公司 | 一种联合或单独检测自身免疫性肝病相关抗体的试剂盒及其检测方法 |
| CN102955027A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体抗lc-1抗体的试剂盒及其检测方法 |
| CN102955026A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体asma的试剂盒及其检测方法 |
| CR20230131A (es) | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EP3477303A1 (en) | 2017-10-27 | 2019-05-01 | Medizinische Hochschule Hannover | Method and means for diagnosing autoimmune hepatitis using autoantibody markers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106726A (en) * | 1990-02-16 | 1992-04-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV |
-
1991
- 1991-06-17 FR FR9107363A patent/FR2677653A1/fr active Granted
-
1992
- 1992-06-16 EP EP92912543A patent/EP0589993B1/fr not_active Expired - Lifetime
- 1992-06-16 WO PCT/FR1992/000539 patent/WO1992022656A1/fr not_active Ceased
- 1992-06-16 DE DE69229269T patent/DE69229269T2/de not_active Expired - Fee Related
- 1992-06-16 ES ES92912543T patent/ES2133320T3/es not_active Expired - Lifetime
- 1992-06-16 US US08/162,149 patent/US5830667A/en not_active Expired - Lifetime
- 1992-06-16 CA CA002111672A patent/CA2111672A1/en not_active Abandoned
- 1992-06-16 JP JP50076893A patent/JP3284240B2/ja not_active Expired - Fee Related
- 1992-06-16 AT AT92912543T patent/ATE180512T1/de not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．Ｕ．Ｓ．Ａ．，米国，１９８８年１１月 １日，８５，Ｐ８２５６−８２６０ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0589993A1 (fr) | 1994-04-06 |
| JPH06510663A (ja) | 1994-12-01 |
| US5830667A (en) | 1998-11-03 |
| ATE180512T1 (de) | 1999-06-15 |
| ES2133320T3 (es) | 1999-09-16 |
| CA2111672A1 (en) | 1992-12-23 |
| DE69229269T2 (de) | 1999-11-11 |
| FR2677653A1 (fr) | 1992-12-18 |
| FR2677653B1 (enExample) | 1995-04-14 |
| EP0589993B1 (fr) | 1999-05-26 |
| WO1992022656A1 (fr) | 1992-12-23 |
| DE69229269D1 (de) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KOTANI et al. | Detection of autoantibodies to thyroid peroxidase in autoimmune thyroid diseases by micro-ELISA and immunoblotting | |
| Richardson et al. | Procyclin: an unusual immunodominant glycoprotein surface antigen from the procyclic stage of African trypanosomes | |
| JP3284240B2 (ja) | ヒトチトクロームｐ４５０ｉｉｄ６由来ペプチド断片、抗ペプチド断片抗体、及びそれらの自己免疫性肝炎の診断における応用 | |
| EP0683234B1 (en) | Antibody against beta-amyloid or their derivative and use thereof | |
| Helbig et al. | Serological differentiation between cystic and alveolar echinococcosis by use of recombinant larval antigens | |
| Olafsson et al. | Production, characterization and use of monoclonal antibodies against the major extracellular human cysteine proteinase inhibitors cystatin C and kininogen | |
| Magnusson et al. | Antigenic analysis of the second extra-cellular loop of the human beta-adrenergic receptors | |
| US5606026A (en) | Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1 | |
| KR100328112B1 (ko) | 류마토이드관절염병원관련관절염성펩티드에대항하는면역보호유도에유용한백신조성물과방법 | |
| US20020110871A1 (en) | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 | |
| Chamekh et al. | Diagnostic value of a synthetic peptide derived from Echinococcus granulosus recombinant protein. | |
| JP5174659B2 (ja) | リウマチ疾患の診断方法 | |
| Asano et al. | Immunochemical and immunohistochemical localization of the G protein G11 in rat central nervous tissues | |
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| Allan et al. | Antibodies to the carboxyl terminus of human apolipoprotein AI. The putative cellular binding domain of high density lipoprotein 3 and carboxyl-terminal structural homology between apolipoproteins AI and A-II. | |
| JP2002537783A (ja) | Ｔ．ｃｒｕｚｉ感染の検出および予防のための、化合物および方法 | |
| Abréu Vélez et al. | The tryptic cleavage product of the mature form of the bovine desmoglein I ectodomain is one of the antigen moieties immunoprecipitated by all sera from symptomatic patients affected by a new variant of endemic pemphigus | |
| JPH03500964A (ja) | プロタミン反応性ＩｇＭ抗体 | |
| Memar et al. | Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular, domain of the pemphigus vulgaris antigen (desmoglein 3). | |
| CA2259413A1 (en) | Methods for determining the presence of brain protein s-100 | |
| AU696646B2 (en) | Method and reagents for the treatment of rheumatoid arthritis | |
| JP5156997B2 (ja) | Ｉｖ型コラーゲン様免疫活性ペプチド | |
| CA1341391C (en) | Protective peptides derived from human immunodeficiency virus-1 gp160 | |
| Williams Jr et al. | Differential mapping of Fc gamma-binding and monoclonal antibody-reactive epitopes on gE, the Fc gamma-binding glycoprotein of herpes simplex virus type 1. | |
| Costopoulou et al. | Direct ELISA method for the specific determination of prothymosin alpha in human specimens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090308 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100308 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110308 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |